"Like I've just written on another thread, CSL expensed US$1.1B in research and development which was an increase of 10% from the previous years R&D spend.
If they cut that spend by a half and put the US$550M in the NPAT column to ensure that they easily beat consensus, then the SP would be closer to $350 rather than $250."
For starters, US$550m would not drop down to NPAT, because it would need to be tax affected.
Second, the R&D spend is what drives the growth.
And it is the market's expectation of a certain level of growth that informs the valuation multiple.
Ergo:
1.) Less expenditure that drives growth implies lower rate of growth.
2.) Lower rate of growth implies lower valuation multiple.
When it comes to valuation theory, there's no such thing as a free lunch, I'm afraid.
- Forums
- ASX - By Stock
- CSL
- Ann: Market Update
Ann: Market Update, page-32
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$305.34 |
Change
4.220(1.40%) |
Mkt cap ! $147.5B |
Open | High | Low | Value | Volume |
$303.92 | $305.98 | $302.00 | $378.0M | 1.257M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 74 | $305.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$305.43 | 250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 74 | 305.220 |
1 | 32 | 304.540 |
1 | 4955 | 304.350 |
1 | 4649 | 304.170 |
1 | 1593 | 304.020 |
Price($) | Vol. | No. |
---|---|---|
305.900 | 200 | 1 |
305.950 | 150 | 1 |
305.990 | 100 | 1 |
306.000 | 639 | 6 |
306.250 | 50 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |